Kenneth E. Rittle

3.9k total citations · 1 hit paper
38 papers, 2.5k citations indexed

About

Kenneth E. Rittle is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, Kenneth E. Rittle has authored 38 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 15 papers in Cellular and Molecular Neuroscience and 13 papers in Organic Chemistry. Recurrent topics in Kenneth E. Rittle's work include Neuropeptides and Animal Physiology (13 papers), Chemical Synthesis and Analysis (12 papers) and Peptidase Inhibition and Analysis (5 papers). Kenneth E. Rittle is often cited by papers focused on Neuropeptides and Animal Physiology (13 papers), Chemical Synthesis and Analysis (12 papers) and Peptidase Inhibition and Analysis (5 papers). Kenneth E. Rittle collaborates with scholars based in United States and United Kingdom. Kenneth E. Rittle's co-authors include B. Evans, Robert M. DiPardo, Mark G. Bock, Daniel F. Veber, Roger Freidinger, Willie L. Whitter, Paul Anderson, James P. Springer, G. F. Lundell and Victor J. Lotti and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Controlled Release and Journal of Medicinal Chemistry.

In The Last Decade

Kenneth E. Rittle

38 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists

1988 1.2k citations B. Evans, Kenneth E. Rittle et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kenneth E. Rittle United States	20	1.3k	1.3k	585	278	255	38	2.5k
Robert M. DiPardo United States	21	1.4k 1.0×	1.5k 1.1×	680 1.2×	260 0.9×	218 0.9×	57	2.7k
B. Evans United States	21	1.4k 1.0×	1.6k 1.2×	660 1.1×	264 0.9×	217 0.9×	56	2.9k
Willie L. Whitter United States	13	1.0k 0.8×	1.1k 0.8×	528 0.9×	228 0.8×	197 0.8×	19	2.0k
Mark G. Bock United States	29	1.8k 1.3×	1.9k 1.5×	875 1.5×	326 1.2×	244 1.0×	109	3.8k
William J. Greenlee United States	34	2.0k 1.5×	2.2k 1.7×	642 1.1×	338 1.2×	429 1.7×	161	4.5k
John Saunders United States	28	1.3k 1.0×	1.3k 1.0×	410 0.7×	145 0.5×	126 0.5×	139	3.1k
Maurizio Anzini Italy	32	1.4k 1.1×	880 0.7×	340 0.6×	338 1.2×	157 0.6×	111	2.5k
John W. Clader United States	28	1.4k 1.0×	953 0.7×	227 0.4×	203 0.7×	230 0.9×	72	3.1k
Stephen W. Kaldor United States	20	1.4k 1.0×	1.2k 0.9×	209 0.4×	112 0.4×	134 0.5×	36	2.6k
Sander G. Mills United States	30	1.2k 0.9×	1.2k 0.9×	381 0.7×	123 0.4×	73 0.3×	77	2.6k

Countries citing papers authored by Kenneth E. Rittle

Since Specialization

Citations

This map shows the geographic impact of Kenneth E. Rittle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth E. Rittle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth E. Rittle more than expected).

Fields of papers citing papers by Kenneth E. Rittle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth E. Rittle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth E. Rittle. The network helps show where Kenneth E. Rittle may publish in the future.

Co-authorship network of co-authors of Kenneth E. Rittle

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth E. Rittle. A scholar is included among the top collaborators of Kenneth E. Rittle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth E. Rittle. Kenneth E. Rittle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barrow, James C., Kenneth E. Rittle, Harold G. Selnick, et al.. (2007). Design and Synthesis of 2,3,5‐Substituted Imidazolidin‐4‐one Inhibitors of BACE‐1. ChemMedChem. 2(7). 995–999. 31 indexed citations

Stauffer, Shaun R., Matthew G. Stanton, Alison R. Gregro, et al.. (2006). Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind β-secretase in a N-terminal 10s-loop down conformation. Bioorganic & Medicinal Chemistry Letters. 17(6). 1788–1792. 37 indexed citations

Rittle, Kenneth E., James C. Barrow, Julie A. Krueger, et al.. (2003). Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position. Bioorganic & Medicinal Chemistry Letters. 13(20). 3477–3482. 20 indexed citations

Nantermet, Philippe G., James C. Barrow, G. F. Lundell, et al.. (2002). Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1). Bioorganic & Medicinal Chemistry Letters. 12(3). 319–323. 32 indexed citations

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1994). ChemInform Abstract: Development of 1,4‐Benzodiazepine Cholecystokinin Type B Antagonists.. ChemInform. 25(26). 3 indexed citations

Evans, B., G. F. Lundell, Kevin F. Gilbert, et al.. (1993). Nanomolar-affinity, non-peptide oxytocin receptor antagonists. Journal of Medicinal Chemistry. 36(25). 3993–4005. 19 indexed citations

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1993). Development of 1,4-benzodiazepine cholecystokinin type B antagonists. Journal of Medicinal Chemistry. 36(26). 4276–4292. 51 indexed citations

Evans, B., James L. Leighton, Kenneth E. Rittle, et al.. (1992). Orally active, nonpeptide oxytocin antagonists. Journal of Medicinal Chemistry. 35(21). 3919–3927. 64 indexed citations

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1990). Cholecystokinin-A receptor ligands based on the .kappa.-opioid agonist tifluadom. Journal of Medicinal Chemistry. 33(1). 450–455. 16 indexed citations

10.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1989). Benzodiazepine gastrin and brain cholecystokinin receptor ligands; L-365,260. Journal of Medicinal Chemistry. 32(1). 13–16. 250 indexed citations

11.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1988). Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines. Journal of Medicinal Chemistry. 31(1). 176–181. 16 indexed citations

12.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1988). Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines. Journal of Medicinal Chemistry. 31(1). 264–268. 18 indexed citations

13.

Evans, B., Kenneth E. Rittle, Mark G. Bock, et al.. (1988). Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. Journal of Medicinal Chemistry. 31(12). 2235–2246. 1177 indexed citations breakdown →

14.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1987). Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini. Journal of Medicinal Chemistry. 30(10). 1853–1857. 9 indexed citations

15.

Rittle, Kenneth E., B. Evans, Mark G. Bock, et al.. (1987). A new amine resolution method and its application to 3-aminobenzodiazepines. Tetrahedron Letters. 28(5). 521–522. 20 indexed citations

16.

Bock, Mark G., Robert M. DiPardo, B. Evans, et al.. (1987). An expedient synthesis of 3-amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one. Tetrahedron Letters. 28(9). 939–942. 14 indexed citations

17.

Bock, Mark G., Robert M. DiPardo, Kenneth E. Rittle, et al.. (1986). Cholecystokinin antagonists. Synthesis of asperlicin analogs with improved potency and water solubility. Journal of Medicinal Chemistry. 29(10). 1941–1945. 24 indexed citations

18.

Evans, B., Paul Anderson, Marcia E. Christy, et al.. (1980). ChemInform Abstract: TRANSANNULAR REACTIONS OF DIBENZO(A,D)CYCLOALKENES. 2. SYNTHESIS OF BRIDGEHEAD SUBSTITUTED DIBENZO(A,D)CYCLOALKENIMINES BY A REGIOSPECIFIC TRANSANNULAR AMINE TO OLEFIN ADDITION. Chemischer Informationsdienst. 11(3). 4 indexed citations

19.

Randall, William C., Paul Anderson, Emlen L. Cresson, et al.. (1979). Synthesis, assignment of absolute configuration, and receptor binding studies relevant to the neuroleptic activities of a series of chiral 3-substituted cyproheptadine atropisomers. Journal of Medicinal Chemistry. 22(10). 1222–1230. 20 indexed citations

20.

Remy, David C., Kenneth E. Rittle, C. A. HUNT, et al.. (1977). Synthesis and stereospecific antipsychotic activity of (-)-1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine. Journal of Medicinal Chemistry. 20(8). 1013–1019. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact